Evaluation of Prolonged Fatigue Post–West Nile Virus Infection and Association of Fatigue with Elevated Antiviral and Proinflammatory Cytokines

Melissa Garcia

Anne Hause

Christopher Walker

Jordan Orange

Rodrigo Hasbun

Kristy Murray

^{Section of Pediatric Tropical Medicine, Baylor College of Medicine, National School of Tropical Medicine, Houston, Texas.}

^{School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas.}

^{Section of Immunology, Department of Pediatrics, Baylor College of Medicine, National School of Tropical Medicine, Houston, Texas.}

^{Medical School, University of Texas Health Science Center at Houston, Houston, Texas.}

^{Corresponding author.}

Address correspondence to:, Dr. Kristy O. Murray, Section of Pediatric Tropical Medicine, National School of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, E-mail:Email: ude.mcb@yarruMK

Abstract

This study aimed to characterize fatigue postinfection among study participants with a history of West Nile virus (WNV) infection and determine whether antiviral and pro-inflammatory cytokines were significantly elevated in those reporting prolonged fatigue. We found that 31% (44/140) of study participants experienced prolonged (more than 6 months) fatigue postinfection, with an average length of fatigue duration of 5 years. Females, those younger than 50 years of age, and those with symptomatic clinical WNV disease were significantly more likely to report fatigue. Pro-inflammatory and antiviral cytokines (granulocyte macrophage colony stimulating factor, interferon-γ, interferon-γ inducing protein 10, interleukin 2, interleukin 6, and interleukin 12p70) were significantly elevated in those reporting fatigue postinfection compared to those not reporting fatigue. Clinicians should consider history of WNV infection as a possible factor when evaluating causes of prolonged fatigue following a febrile viral illness in their patients.

Abstract

References

1. Arnett SV, Alleva LM, Korossy-Horwood R, and Clark IA. Chronic fatigue syndrome—a neuroimmunological model. Med Hypotheses 2011;77:77–83 [[PubMed]
2. Carson PJ, Konewko P, Wold KS, et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis 2006;43:723–730 [[PubMed]
3. Centers for Disease Control and Prevention. West Nile Virus disease and other arboviral diseases—United States, 2011. Morbid Mortal Wkly Rep 2012;61:510–514 [[PubMed]
4. Centers for Disease Control and Prevention. QuickStats: percentage of adults who often felt very tired or exhausted in the past 3 months, by sex and age group—national health interview survey, United States, 2010. Morbidity and Mortality Weekly Report 2013;62:275 [PubMed]
5. Craig T, and Kakumanu S. Chronic fatigue syndrome: evaluation and treatment. Am Fam Physician 2002;65:1083–1090 [[PubMed]
6. Devanur LD, and Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006;37:139–150 [[PubMed]
7. Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503–508 [[PubMed]
8. Encabo A, Solves P, Mateu E, et al. Selective generation of different dendritic cell precursors from CD34+ cells by interleukin-6 and interleukin-3. Stem Cells 2004;22:725–740 [[PubMed]
9. Finsterer J, and Mahjoub SZ. Fatigue in healthy and diseased individuals. Am J Hosp Palliat Care 2013July26 [Epub ahead of print] [[PubMed]
10. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953–959 [[PubMed]
11. Gee K, Guzzo C, Che Mat NF, Ma W, and Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009;8:40–52 [[PubMed]
12. Hamilton JA, and Anderson GP. GM-CSF biology. Growth Factors 2004;22:225–231 [[PubMed]
13. Komaroff AL, and Cho TA. Role of infection and neurologic dysfunction in chronic fatigue syndrome. Semin Neurol 2011;31:325–337 [[PubMed]
14. Leis AA, and Stokic DS. Neuromuscular manifestations of west nile virus infection. Front Neurol 2012;3:37.
15. Lindsey NP, Sejvar JJ, Bode AV, Pape WJ, and Campbell GL. Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003. Vector Borne Zoonotic Dis 2012;12:230–235 [[PubMed]
16. Lorusso L, Mikhaylova SV, Capelli E, et al. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009;8:287–291 [[PubMed]
17. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001;358:261–264 [[PubMed]
18. Murray K, Walker C, Herrington E, et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis 2010;201:2–4
19. Murray KO, Garcia MN, Yan C, and Gorchakov R. Persistence of detectable immunoglobulin m antibodies up to 8 years after infection with West Nile virus. Am J Trop Med Hyg 2013;89:996–1000
20. Murray KO, Garcia MN, Rahbar MH, Martinez D, Khuwaja SA, Arafat RR, and Rossmann S. Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort. PLoS One 2014;9:e102953.
21. Nolan MS, Hause AM, and Murray KO. Findings of long-term depression up to 8 years post infection from West Nile virus. J Clin Psychol 2012;68:801–808
22. Papa A, Danis K, Athanasiadou A, Delianidou M, and Panagiotopoulos T. Persistence of West Nile virus immunoglobulin M antibodies, Greece. J Med Virol 2011;83:1857–1860 [[PubMed]
23. Patarca R, Klimas NG, Lugtendorf S, Antoni M, and Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 1994;18:S147–153 [[PubMed]
24. Petersen LR, Carson PJ, Biggerstaff BJ, et al. Estimated cumulative incidence of West Nile virus infection in US adults, 1999–2010. Epidemiol Infect 2013;141:591–595 [[PubMed]
25. Pogodina VV, Frolova MP, Malenko GV, et al. Study on West Nile virus persistence in monkeys. Arch Virol 1983;75:71–86 [[PubMed]
26. Prince HE, Tobler LH, Lape-Nixon M, et al. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol 2005;43:4316–4320
27. Raison CL, Lin JM, and Reeves WC. Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun 2009;23:327–337 [[PubMed]
28. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003;9:376–379
29. Shirato K, Miyoshi H, Kariwa H, and Takashima I. The kinetics of proinflammatory cytokines in murine peritoneal macrophages infected with envelope protein-glycosylated or non-glycosylated West Nile virus. Virus Res 2006;121:11–16 [[PubMed]
30. Siddharthan V, Wang H, Motter NE, et al. Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation. J Virol 2009;83:4251–4261
31. Stewart BS, Demarest VL, Wong SJ, Green S, and Bernard KA. Persistence of virus-specific immune responses in the central nervous system of mice after West Nile virus infection. BMC Immunol 2011;12:6.
32. The Consortium of Multiple Sclerosis Centers Health Services Research Subcomittee. Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York, NY: National Multiple Sclerosis Society, 1997 [PubMed]
33. Thompson R. Viral hepatitis: mechanism of fatigue in patients with chronic hepatitis C involves carnitine. Nat Rev Gastroenterol Hepatol 2011;8:246. [[PubMed]
34. Vernon SD, Whistler T, Aslakson E, Rajeevan M, and Reeves WC. Challenges for molecular profiling of chronic fatigue syndrome. Pharmacogenomics 2006;7:211–218 [[PubMed]